Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(23):1803-1806; doi:10.1093/jnci/94.23.1803
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Polsky, D.
Right arrow Articles by Osman, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polsky, D.
Right arrow Articles by Osman, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 23, 1803-1806, December 4, 2002
© 2002 Oxford University Press

BRIEF COMMUNICATION

HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma

David Polsky, Kate Melzer, Carole Hazan, Katherine S. Panageas, Klaus Busam, Maria Drobnjak, Hideko Kamino, Joanna G. Spira, Alfred W. Kopf, Alan Houghton, Carlos Cordon-Cardo, Iman Osman

Affiliations of authors: D. Polsky, K. Melzer, C. Hazan, H. Kamino, J. G. Spira, A. W. Kopf, Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York; I. Osman, Ronald O. Perelman Department of Dermatology, Department of Urology, and Kaplan Comprehensive Cancer Center, New York University School of Medicine; K. S. Panageas (Department of Epidemiology and Biostatistics), K. Busam, M. Drobnjak, C. Cordon-Cardo (Department of Pathology), A. Houghton (Department of Immunology), Memorial Sloan-Kettering Cancer Center, New York.

Correspondence to: Iman Osman, M.D., New York University Medical Center, 550 1st Ave., Department of Dermatology, H-100, New York, NY 10016 (e-mail: Iman.Osman{at}med.nyu.edu).

ABSTRACT

Overexpression of the oncogene HDM2 is observed in a substantial proportion of melanomas, including noninvasive and thin lesions, suggesting that HDM2 overexpression may be an early event in melanocyte transformation. To determine the role of HDM2 in the clinical progression of melanoma, we examined whether its expression was associated with patient survival. From November 1972 through November 1982, 134 patients with melanoma who participated in the New York University Melanoma Cooperative Group were studied, if representative tissues and follow-up were available. HDM2 protein expression was assessed immunohistochemically. Unexpectedly, we observed that HDM2 overexpression was statistically significantly associated with improved disease-free survival (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.89; two-sided {chi}2 P = .021) and overall survival (RR = 0.55, 95% CI = 0.33 to 0.94; two-sided {chi}2 P = .027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. F. Firoz, M. Warycha, J. Zakrzewski, D. Pollens, G. Wang, R. Shapiro, R. Berman, A. Pavlick, P. Manga, H. Ostrer, et al.
Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma
Clin. Cancer Res., April 1, 2009; 15(7): 2573 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani
Toward a Molecular Classification of Melanoma
J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Burger, Y. Gao, Y. Amemiya, H. J. Kahn, R. Kitching, Y. Yang, P. Sun, S. A. Narod, W. M. Hanna, and A. K. Seth
A Novel RING-Type Ubiquitin Ligase Breast Cancer-Associated Gene 2 Correlates with Outcome in Invasive Breast Cancer
Cancer Res., November 15, 2005; 65(22): 10401 - 10412.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Berger, R. L. Camp, K. A. DiVito, H. M. Kluger, R. Halaban, and D. L. Rimm
Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome
Cancer Res., December 1, 2004; 64(23): 8767 - 8772.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. I. Bardos, N.-M. Chau, and M. Ashcroft
Growth Factor-Mediated Induction of HDM2 Positively Regulates Hypoxia-Inducible Factor 1{alpha} Expression
Mol. Cell. Biol., April 1, 2004; 24(7): 2905 - 2914.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Onel and C. Cordon-Cardo
MDM2 and Prognosis
Mol. Cancer Res., January 1, 2004; 2(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.